| Quantity | 1 mg, 5 mg, 10 mg | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | 100 mg, 500 mg, 1 g, 5 g, 10 g | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | 500 µ, g, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |
| Description | Myhc-α(334–352) is a sequence fragment of amino acid residues 334 to 352 of cardiac myosin heavy chain α. Myhc-α(334–352) is an immunodominant epitope that can induce autoimmune reactions in A/J mice, leading to the occurrence of myocarditis. Myhc-α(334–352) canMyhc-α(334–352) is a sequence fragment of amino acid residues 334 to 352 of cardiac myosin heavy chain α. Myhc-α(334–352) is an immunodominant epitope that can induce autoimmune reactions in A/J mice, leading to the occurrence of myocarditis. Myhc-α(334–352) can be used to study the autoimmune pathways of myocarditis and dilated cardiomyopathy[1]... Read More | Lonodelestat TFA (POL6014 TFA) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat TFA has the potential for the research of cystic fibrosis (CF)[1][2][3] | Papain is a cysteine protease of the peptidase C1 family, which is used in food, pharmaceutical, textile, and cosmetic industries | Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis[1][2] | WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)... Read More |